NCT00663338

Dopamine Agonist for Hemispatial Neglect and Motor Deficit Post Stroke

A Multi-centre Exploratory Study to Evaluate the Efficacy of the Dopamine Receptor Agonist Rotigotine in the Treatment of Hemispatial Neglect and Motor Deficits Following Stroke

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: University College, London · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is to assess the effect of the drug rotigotine on the syndrome of hemispatial neglect and motor deficits following strokes affecting the right hemisphere of the brain.

Detailed description

Hemispatial neglect and motor deficits remain major problems following right-hemisphere stroke. This study aims to assess the effect of rotigotine on hemispatial neglect, its component cognitive deficits (including spatial working memory and sustained attention) and motor deficits following right-hemisphere stroke.

Conditions

• Right Hemisphere Stroke
• Hemispatial Neglect
• Motor Deficit

Interventions

Type	Name	Description
DRUG	Rotigotine	Rotigotine 9.0mg patch (equivalent to 4mg/24hr transdermal absorption) once daily during the treatment phase.

Timeline

• Start date: 2010-01-01
• Primary completion: 2010-06-01
• Completion: 2010-07-01
• First posted: 2008-04-22
• Last updated: 2011-02-21

Locations

3 sites across 1 country: United Kingdom